Should I buy or sell BioCryst Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares. View BCRX analyst ratings or view top-rated stocks .

What is BioCryst Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 1 year price objectives for BioCryst Pharmaceuticals' stock. Their BCRX share price targets range from $10.00 to $30.00. On average, they predict the company's share price to reach $13.22 in the next twelve months. This suggests a possible upside of 139.5% from the stock's current price. View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts .

How have BCRX shares performed in 2023?

BioCryst Pharmaceuticals' stock was trading at $11.48 at the beginning of 2023. Since then, BCRX shares have decreased by 51.9% and is now trading at $5.52. View the best growth stocks for 2023 here .

When is BioCryst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our BCRX earnings forecast .

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.06. The biotechnology company earned $86.74 million during the quarter, compared to analysts' expectations of $86.54 million.

What ETFs hold BioCryst Pharmaceuticals' stock?

ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , ETFMG Treatments Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP) . ALPS Medical Breakthroughs ETF (SBIO) .

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com . Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO) , El Pollo Loco (LOCO) , Advanced Micro Devices (AMD) , Idera Pharmaceuticals (IDRA) , OPKO Health (OPK) , Dynavax Technologies (DVAX) , La Jolla Pharmaceutical (LJPC) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV) .

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (2.62%), Deerfield Management Company L.P. Series C (1.60%), Kynam Capital Management LP (1.53%), FMR LLC (1.44%), Rock Springs Capital Management LP (1.25%) and Rice Hall James & Associates LLC (1.20%). Insiders that own company stock include Alane P Barnes , Anthony Doyle , George B Abercrombie, George B Abercrombie , Helen M Thackray, Jon P Stonehouse , Machelle Sanders, Michael L Jones, Nancy J Hutson , Vincent Milano , William P Sheridan and Yarlagadda S Babu . View institutional ownership trends .

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

BioCryst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BCRX)

$5.52

+0.01 (+0.18%)

(As of 02:33 PM ET)

Compare

Today's Range: $5.42
▼
$6.00
50-Day Range: $4.98
▼
$7.24
52-Week Range: $4.82
▼
$12.07

Volume: 6.52 million shs
Average Volume: 2.92 million shs
Market Capitalization: $1.13 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.22

BioCryst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 139.5% Upside
$13.22 Price Target
Short Interest: Bearish
14.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.85
Upright™ Environmental Score
News Sentiment: 1.60
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.94) to ($0.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

333rd out of 958 stocks

Biological Products, Except Diagnostic Industry

51st out of 146 stocks

3.5

Analyst's Opinion

Consensus Rating
BioCryst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.22, BioCryst Pharmaceuticals has a forecasted upside of 139.5% from its current price of $5.52.
Amount of Analyst Coverage
BioCryst Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.39% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
Change versus previous month
Short interest in BioCryst Pharmaceuticals has recently decreased by 2.19%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
BioCryst Pharmaceuticals does not currently pay a dividend.
Dividend Growth
BioCryst Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.
Environmental Sustainability
The Environmental Impact score for BioCryst Pharmaceuticals is -1.85.

3.7

News and Social Media Coverage

News Sentiment
BioCryst Pharmaceuticals has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for BioCryst Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
13 people have searched for BCRX on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.
MarketBeat Follows
4 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of BioCryst Pharmaceuticals is held by insiders.
Percentage Held by Institutions
91.46% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.94) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioCryst Pharmaceuticals is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioCryst Pharmaceuticals is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCRX Stock News Headlines

December 7, 2023 | markets.businessinsider.com

Buy Recommendation for BioCryst Pharmaceuticals Amid Strong Orladeyo Market Position and Positive Revenue Projections

December 1, 2023 | finance.yahoo.com

J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 29, 2023 | finance.yahoo.com

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

November 28, 2023 | americanbankingnews.com

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $13.22 Consensus Target Price from Brokerages

November 21, 2023 | tmcnet.com

BioCryst Launches ORLADEYO® (berotralstat) in Spain

November 21, 2023 | finance.yahoo.com

BioCryst Launches ORLADEYO® (berotralstat) in Spain

November 12, 2023 | finance.yahoo.com

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) recent 18% pullback adds to one-year year losses, institutional owners may take drastic measures

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 10, 2023 | markets.businessinsider.com

BioCryst: New Analysis Reveals Reduced Attack Rates In HAE With C1-INH Following ORLADEYO Treatment

November 10, 2023 | finance.yahoo.com

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

November 6, 2023 | markets.businessinsider.com

BioCryst’s Strong R&D Capabilities and Expanded Pipeline Drive Analyst’s Buy Recommendation

November 6, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Cidara Therapeutics (CDTX) and Carisma Therapeutics (CARM)

November 6, 2023 | bizjournals.com

BioCryst pays $5M upfront in licensing deal for vision-loss treatment

November 3, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Phathom Pharmaceuticals (PHAT), BioCryst (BCRX)

November 3, 2023 | msn.com

BioCryst, Clearside Biomedical in pact for diabetic eye disease

November 3, 2023 | finance.yahoo.com

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Call Transcript

November 3, 2023 | finance.yahoo.com

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

November 3, 2023 | finance.yahoo.com

BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

November 2, 2023 | finance.yahoo.com

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

November 2, 2023 | finance.yahoo.com

BioCryst Pharmaceuticals Inc (BCRX) Reports Q3 2023 Earnings: ORLADEYO Revenue Up by 29.8% YoY

November 1, 2023 | seekingalpha.com

BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stock's Bear Run

October 26, 2023 | finance.yahoo.com

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

October 20, 2023 | finance.yahoo.com

BioCryst to Host R&D Day on November 3

October 19, 2023 | finance.yahoo.com

BioCryst to Report Third Quarter 2023 Financial Results on November 2

September 26, 2023 | msn.com

RBC Capital Reiterates Biocryst Pharmaceuticals (BCRX) Outperform Recommendation

See More Headlines

Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BCRX
CUSIP: 09058V10
CIK: 882796
Web: www.biocryst.com
Phone: (919) 859-1302
Fax: 919-859-1314
Employees: 531
Year Founded: 1986

Price Target and Rating

Average Stock Price Target: $13.22
High Stock Price Target: $30.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +130.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-247,120,000.00
Net Margins: -74.43%
Pretax Margin: -73.86%
Return on Equity: N/A
Return on Assets: -39.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.54
Quick Ratio: 5.21

Sales & Book Value

Annual Sales: $270.83 million
Price / Sales: 4.33
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.58) per share
Price / Book: -3.63

Miscellaneous

Outstanding Shares: 204,810,000
Free Float: 195,797,000
Market Cap: $1.17 billion
Optionable: Optionable
Beta: 1.87

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Jon P. Stonehouse (Age 62)
CEO, President & Executive Director
Comp: $1.15M
Mr. Anthony J. Doyle (Age 43)
Senior VP & CFO
Comp: $726.42k
Ms. Alane P. Barnes (Age 57)
Senior VP, Chief Legal Officer & Corporate Secretary
Comp: $655.33k
Dr. William P. Sheridan MBBS (Age 68)
Chief Development Officer
Comp: $784.09k
Dr. Yarlagadda S. Babu (Age 70)
Chief Discovery Officer
Comp: $691.45k
Dr. Helen M. Thackray FAAP (Age 55)
M.D., Chief Research & Development Officer
Comp: $844k
Mr. Charles K. Gayer (Age 52)
Senior VP & Chief Commercial Officer
Comp: $643.43k
Mr. Michael L. Jones (Age 53)
Executive Director of Finance & Principal Accounting Officer
Mr. John D. Bluth (Age 50)
Chief Communications Officer
Ms. Stephanie Angelini
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings or view top-rated stocks.
What is BioCryst Pharmaceuticals' stock price target for 2024?: 8 equities research analysts have issued 1 year price objectives for BioCryst Pharmaceuticals' stock. Their BCRX share price targets range from $10.00 to $30.00. On average, they predict the company's share price to reach $13.22 in the next twelve months. This suggests a possible upside of 139.5% from the stock's current price.
View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts.
How have BCRX shares performed in 2023?: BioCryst Pharmaceuticals' stock was trading at $11.48 at the beginning of 2023. Since then, BCRX shares have decreased by 51.9% and is now trading at $5.52.
View the best growth stocks for 2023 here.
When is BioCryst Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our BCRX earnings forecast.
How were BioCryst Pharmaceuticals' earnings last quarter?: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.06. The biotechnology company earned $86.74 million during the quarter, compared to analysts' expectations of $86.54 million.
What ETFs hold BioCryst Pharmaceuticals' stock?: ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?: 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.
What other stocks do shareholders of BioCryst Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).
Who are BioCryst Pharmaceuticals' major shareholders?: BioCryst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (2.62%), Deerfield Management Company L.P. Series C (1.60%), Kynam Capital Management LP (1.53%), FMR LLC (1.44%), Rock Springs Capital Management LP (1.25%) and Rice Hall James & Associates LLC (1.20%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Machelle Sanders, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends.
How do I buy shares of BioCryst Pharmaceuticals?: Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BCRX) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioCryst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BCRX)

BioCryst Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

BCRX Stock Price History

BCRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BCRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™